These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 35862858)

  • 1. Prognostic Value of Programmed Death Ligand-1 in Discriminating Patients With Lymph Node-Negative, p53-Wild-Type, or Low-BRCA1/2-Expression Pancreatic Ductal Adenocarcinoma.
    Chen X; Zhang Y; Mo S; Ma H; Lu Z; Yu S; Chen J
    Arch Pathol Lab Med; 2023 Apr; 147(4):465-473. PubMed ID: 35862858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 and PD-L2 expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and DNA damage response molecules.
    Zhang Y; Chen X; Mo S; Ma H; Lu Z; Yu S; Chen J
    J Pathol Clin Res; 2022 May; 8(3):257-267. PubMed ID: 35037417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of a novel immune checkpoint, Siglec-15, in pancreatic ductal adenocarcinoma.
    Chen X; Mo S; Zhang Y; Ma H; Lu Z; Yu S; Chen J
    J Pathol Clin Res; 2022 May; 8(3):268-278. PubMed ID: 35083884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B7-H3 immune checkpoint expression is a poor prognostic factor in colorectal carcinoma.
    Lu Z; Zhao ZX; Cheng P; Huang F; Guan X; Zhang MG; Chen HP; Liu Z; Jiang Z; Zheng ZX; Zou SM; Wang XS
    Mod Pathol; 2020 Nov; 33(11):2330-2340. PubMed ID: 32514163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of B7 family checkpoint proteins in cervical cancer.
    Zong L; Gu Y; Zhou Y; Kong Y; Mo S; Yu S; Xiang Y; Chen J
    Mod Pathol; 2022 Jun; 35(6):786-793. PubMed ID: 34848831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic ductal adenocarcinoma.
    Chen X; Ma H; Mo S; Zhang Y; Lu Z; Yu S; Chen J
    Front Immunol; 2022; 13():942154. PubMed ID: 35936015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and Prognostic Value of B7 Family Immune Checkpoints in Pancreatic Neuroendocrine Tumors.
    Mo S; Zong L; Chen X; Ban X; Li M; Lu Z; Yu S; Chen J
    Arch Pathol Lab Med; 2023 Feb; 147(2):193-201. PubMed ID: 35671167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression and significance of immune checkpoint B7-homolog 4 in endometrial cancer].
    Zong LJ; Xiang Y; Yu SN; Lu ZH; Chen J; Huang WH
    Zhonghua Fu Chan Ke Za Zhi; 2022 Dec; 57(12):921-931. PubMed ID: 36562226
    [No Abstract]   [Full Text] [Related]  

  • 9. Interplay between B7-H3 and HLA class I in the clinical course of pancreatic ductal adenocarcinoma.
    Cattaneo G; Ventin M; Arya S; Kontos F; Michelakos T; Sekigami Y; Cai L; Villani V; Sabbatino F; Chen F; Sadagopan A; Deshpande V; Moore PA; Ting DT; Bardeesy N; Wang X; Ferrone S; Ferrone CR
    Cancer Lett; 2024 Apr; 587():216713. PubMed ID: 38364961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation.
    MacGregor HL; Sayad A; Elia A; Wang BX; Katz SR; Shaw PA; Clarke BA; Crome SQ; Robert-Tissot C; Bernardini MQ; Nguyen LT; Ohashi PS
    J Immunother Cancer; 2019 Dec; 7(1):357. PubMed ID: 31892360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.
    Diana A; Wang LM; D'Costa Z; Allen P; Azad A; Silva MA; Soonawalla Z; Liu S; McKenna WG; Muschel RJ; Fokas E
    Oncotarget; 2016 Jul; 7(27):40992-41004. PubMed ID: 27329602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance and correlation of PD-L1, B7-H3, B7-H4, and TILs in pancreatic cancer.
    Yang J; Tian Z; Gao H; Xiong F; Cao C; Yu J; Shi W; Zhan Q; Yang C
    BMC Cancer; 2022 May; 22(1):584. PubMed ID: 35624419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes.
    Altan M; Pelekanou V; Schalper KA; Toki M; Gaule P; Syrigos K; Herbst RS; Rimm DL
    Clin Cancer Res; 2017 Sep; 23(17):5202-5209. PubMed ID: 28539467
    [No Abstract]   [Full Text] [Related]  

  • 14. Analysis of PD-L1 promoter methylation combined with immunogenic context in pancreatic ductal adenocarcinoma.
    Chen X; Yu S; Chen J; Chen X
    Cancer Immunol Immunother; 2024 Jun; 73(8):149. PubMed ID: 38833018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma.
    Tessier-Cloutier B; Kalloger SE; Al-Kandari M; Milne K; Gao D; Nelson BH; Renouf DJ; Sheffield BS; Schaeffer DF
    BMC Cancer; 2017 Sep; 17(1):618. PubMed ID: 28870260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC).
    Carvajal-Hausdorf D; Altan M; Velcheti V; Gettinger SN; Herbst RS; Rimm DL; Schalper KA
    J Immunother Cancer; 2019 Mar; 7(1):65. PubMed ID: 30850021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer.
    Imai D; Yoshizumi T; Okano S; Uchiyama H; Ikegami T; Harimoto N; Itoh S; Soejima Y; Aishima S; Oda Y; Maehara Y
    Cancer Med; 2017 Jul; 6(7):1614-1626. PubMed ID: 28602029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pathological features related to onco-immunity and their clinical significance of pancreatic ductal adenocarcinoma].
    Wang CM; Xu CY; Jiang S; Zhou Q; Jiang ZJ; Cheng GP; Wu MJ; Feng TT; Yin WJ
    Zhonghua Bing Li Xue Za Zhi; 2022 May; 51(5):419-424. PubMed ID: 35511637
    [No Abstract]   [Full Text] [Related]  

  • 19. PD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8
    Yamaki S; Yanagimoto H; Tsuta K; Ryota H; Kon M
    Int J Clin Oncol; 2017 Aug; 22(4):726-733. PubMed ID: 28314962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1, B7-H3, and PD-1 expression in immunocompetent vs. immunosuppressed patients with cutaneous squamous cell carcinoma.
    Varki V; Ioffe OB; Bentzen SM; Heath J; Cellini A; Feliciano J; Zandberg DP
    Cancer Immunol Immunother; 2018 May; 67(5):805-814. PubMed ID: 29484464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.